BOLD:NSD-Audentes Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 0.09

Change

0.00 (0.00)%

Market Cap

USD 2.75B

Volume

0.03M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+5.05 (+1.92%)

USD68.72B 34.32 27.50
REGN Regeneron Pharmaceuticals, Inc

+16.60 (+2.98%)

USD60.13B 21.90 16.92
SGEN Seattle Genetics, Inc

+5.52 (+3.08%)

USD31.19B N/A N/A
MRNA Moderna, Inc

+4.30 (+6.60%)

USD26.58B N/A N/A
RPRX Royalty Pharma plc

-0.16 (-0.40%)

USD25.36B 35.72 9.73
ALXN Alexion Pharmaceuticals, Inc

+2.41 (+2.15%)

USD24.64B 30.43 27.52
BGNE BeiGene, Ltd

+5.83 (+2.11%)

USD24.64B N/A N/A
GMAB Genmab A/S

+1.03 (+2.94%)

USD23.46B 28.02 3.06
IMMU Immunomedics, Inc

+0.06 (+0.07%)

USD19.69B N/A N/A
INCY Incyte Corporation

+1.48 (+1.74%)

USD18.80B 47.64 35.20

ETFs Containing BOLD

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -99.85% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.85% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -99.68% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.68% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 26.65% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.65% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 67.94% N/A N/A N/A N/A
Risk Adjusted Return 39.22% N/A N/A N/A N/A
Market Capitalization 2.75B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 7.17 N/A N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -50.57% N/A N/A N/A N/A
Return on Invested Capital -44.49% N/A N/A N/A N/A
Return on Assets -28.42% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.62 N/A N/A N/A N/A
Short Percent 3.96% N/A N/A N/A N/A
Beta 2.19 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike